Pay in 4 interest-free payments of $5.90 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
North America region is leading the Semaglutide Biosimilar and Generic Market.
Dose escalation follows a gradual schedule to minimise gastrointestinal side effects
A synthetic 31-amino acid C18 fatty diacid-conjugated GLP-1 analogue and the most extensively characterised long-acting selective glucagon-like peptide-1 receptor agonist research compound available to laboratories in Ireland and a structurally optimised GLP-1(7-37) analogue incorporating Aib8 substitution for DPP-IV resistance, Arg34Lys substitution eliminating a proteolytic site, and a C18 fatty diacid conjugated via a hydrophilic linker to Lys26 enabling tight reversible albumin binding that produces a circulating half-life of about one week and once-weekly pharmacokinetics activating the GLP-1 receptor through canonical Gs-cAMP-PKA-EPAC2 signal transduction in pancreatic beta cells, hypothalamic appetite-regulating nuclei, brainstem nucleus tractus solitarius, cardiac tissue, and peripheral organs to produce glucose-stimulated insulin secretion potentiation, glucagon suppression, gastric emptying inhibition, pronounced central appetite suppression and body weight reduction, beta cell trophic biology, and cardioprotective signalling
(2022) 'Randomized clinical trial of long-term glutathione supplementation in type 2 diabetes', Antioxidants , 11(5), 1026
